Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Petry, Karl Ulrich ^a   Luyten, Alexander ^a   Justus, Annika ^b   Iftner, Angelika ^c   Strehlke, Sarah ^a   Reinecke Lüthge, Axel ^d   Grunwald, Elisabeth ^e   Schulze Rath, Renate ^f   Iftner, Thomas ^c  

^a Klinikum Wolfsburg   (Germany)

^b Klinische Forschung ^*  (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Klinikum der Stadt Wolfsburg   (Germany)

^e Praxis für Frauenheilkunde ^*  (Germany)

^f Sanofi Pasteur MSD GmbH   (Germany)

Author keywords

CIN; High risk HPV; HPV vaccination; HPV16

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA VIRUS INFECTION; EPIDEMIOLOGICAL DATA; FEMALE; GENITAL SYSTEM DISEASE; GENOTYPE; GERMANY; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 66; INFECTION RISK; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS; WART VIRUS INFECTION;

ADULT; AGE FACTORS; COHORT STUDIES; FEMALE; GERMANY; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84874809698     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-135     Document Type: Article

References (38)

1. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009, 4:8. 10.1186/1750-9378-4-8, 2694995, 19486508.
2. Bosch FX, de Sanjosé S. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003, 31:3-13.
3. Pathirana D, Hillemanns P, Petry KU, Becker N, Brockmeyer NH, Erdmann R, Gissmann L, Grundhewer H, Ikenberg H, Kaufmann AM, Klusmann J, Kopp I, Pfister H, Rzany B, Schneede P, Schneider A, Smola S, Winter-Koch N, Wutzler P, Gross G. Short version of the German evidence-based guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine 2009, 27:4551-4559. 10.1016/j.vaccine.2009.03.086, 19524337.
4. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC) Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24. Centers for Disease Control and Prevention (CDC).
5. European Centre for Disease Prevention and Control Introduction of HPV vaccines in EU countries - an update 2012, Stockholm: ECDC, European Centre for Disease Prevention and Control.
6. Hariri S, Markowitz L. Monitoring HPV vaccine impact: early results and ongoing challenges. J Infect Dis 2012, 206:1633-1635. 10.1093/infdis/jis593, 23087429.
7. Klug SJ, Hukelmann M, Hollwitz B, Düzenli N, Schopp B, Petry KU, Iftner T. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 2007, 79:616-625. 10.1002/jmv.20863, 17385693.
8. Luyten A, Theiler KG, Pietralla M, Braun BE, Reinecke-Lüthge A, Petry KU. Primary HPV-screening project in Wolfsburg, Germany. Experience over 18 months. Geburtsh Frauenheilk 2008, 68:273.
9. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003, 88:1570-1577. 10.1038/sj.bjc.6600918, 2377109, 12771924.
10. Iftner T, Eberle S, Iftner A, Holz B, Banik N, Quint W, Straube AN. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol 2010, 82:1928-1939. 10.1002/jmv.21910, 20872721.
11. Petry KU, Breugelmans JG, Benard S, Lamure E, Littlewood KJ, Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol 2008, 29:345-349.
12. Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Schulze-Rath R, Iftner T. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis 2012, 12:367. 10.1186/1471-2334-12-367, 3536688, 23259726.
13. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, Snijders PJF, Petry KU, Krüger Kjaer S, Munk C, Iftner T. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008, 80:1264-1274. 10.1002/jmv.21191, 18461626.
14. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El GF. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005, 6:204. 10.1016/S1470-2045(05)70086-3, 15830458.
15. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527. 10.1056/NEJMoa021641, 12571259, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.
16. Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany-experience over 3 years. J Clin Virol 2009, 46(Suppl 3):S5-10.
17. Walker P, Dexeus S, De Palo G, Barrasso R, Campion M, Girardi F, Jakob C, Roy M. International terminology of colposcopy: an updated report from the international federation for cervical pathology and colposcopy. Obstet Gynecol 2003, 101:175-177. 10.1016/S0029-7844(02)02581-4, 12517664.
18. Colditz GA, Miller JN, Mosteller F. Measuring gain in the evaluation of medical technology. The probability of a better outcome. Int J Technol Assess Health Care 1988, 4:637-642. 10.1017/S0266462300007728, 10291102.
19. Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, Lacey CJ, Beddows S, Soldan K. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ 2012, 344:e4168. 10.1136/bmj.e4168, 3382227, 22730542.
20. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009, 384:410-414. 10.1016/j.virol.2008.10.004, 18986661.
21. Howell-Jones R, de Silva N, Akpan M, Oakeshott P, Carder C, Coupland L, Sillis M, Mallinson H, Ellis V, Frodsham D, Robinson TI, Gill ON, Beddows S, Soldan K. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 2012, 30:3867-3875. 10.1016/j.vaccine.2012.04.006, 22516212.
22. Pista A, de Oliveira CF, Cunha MJ, Paixao MT, Real O, CLEOPATRE Portugal Study Group Risk factors for human papillomavirus infection among women in Portugal: the CLEOPATRE Portugal study. Int J Gynaecol Obstet 2012, 118:112-116. 10.1016/j.ijgo.2012.03.028, 22608026, CLEOPATRE Portugal Study Group.
23. Pista A, de Oliveira CF, Cunha MJ, Paixao MT, Real O, CLEOPATRE Portugal Study Group Prevalence of human papillomavirus infection in women in Portugal: the CLEOPATRE Portugal study. Int J Gynecol Cancer 2011, 21:1150-1158. 10.1097/IGC.0b013e31821dd3b2, 21792018, CLEOPATRE Portugal Study Group.
24. Giorgi Rossi P, Bisanzi S, Paganini I, Di Iasi A, Angeloni C, Scalisi A, Macis R, Pini MT, Chini F, Carozzi FM, HPV Prevalence Italian Working Group Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis 2010, 10:214. 2916912, 20646310, HPV Prevalence Italian Working Group.
25. Piana A, Sotgiu G, Castiglia P, Pischedda S, Cocuzza C, Capobianco G, Marras V, Dessole S, Muresu E. Prevalence and type distribution of human papillomavirus infection in women from north Sardinia Italy. BMC Publ Health 2011, 11:785.
26. Johnson AM, Mercer CH, Beddows S, de Silva N, Desai S, Howell-Jones R, Carder C, Sonnenberg P, Fenton KA, Lowndes C, Soldan K. Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect 2012, 88:212-217. 10.1136/sextrans-2011-050306, 3308471, 22261135.
27. Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 2009, 18:321-330. 10.1158/1055-9965.EPI-08-0510, 19124515.
28. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC, ARTISTIC Study Group Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008, 98:1704-1709. 10.1038/sj.bjc.6604324, 2391119, 18392052, ARTISTIC Study Group.
29. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004, 57:68-72. 10.1136/jcp.57.1.68, 1770158, 14693839.
30. Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, Bekkers RL. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One 2008, 3:e3743. 10.1371/journal.pone.0003743, 2581437, 19011683.
31. Schmeink CE, Melchers WJ, Siebers AG, Quint WG, Massuger LF, Bekkers RL. Human papillomavirus persistence in young unscreened women, a prospective cohort study. PLoS One 2011, 6:e27937. 10.1371/journal.pone.0027937, 3223200, 22132173.
32. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009, 45:2632-2639. 10.1016/j.ejca.2009.07.019, 19709878.
33. Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488. 10.1093/jnci/djq356, 2950170, 20841605.
34. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K, for the HERACLES/SCALE Study Group Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 2013, 132(4):854-67. Epub 2012 Jul 24, 10.1002/ijc.27713, 22752992, for the HERACLES/SCALE Study Group.
35. Brotherton JM, Tabrizi SN, Garland SM. Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? an important issue for postvaccination surveillance. Future Microbiol 2012, 7:193-199. 10.2217/fmb.11.161, 22324989.
36. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206:1645-1651. 10.1093/infdis/jis590, 23087430.
37. Brismar-Wendel S, Froberg M, Hjerpe A, Andersson S, Johansson B. Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer 2009, 101:511-517. 10.1038/sj.bjc.6605165, 2720239, 19623178.
38. Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H, Study Group Collaborators Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010, 103:209-216. 10.1038/sj.bjc.6605747, 2906740, 20628396, Study Group Collaborators.